On Twitter, the Center for Genetic Engineering and Biotechnology (CIGB) said that thanks to the go-getting decision to join efforts and resources with the Food Information and Control Agency (AICA), the Abdala candidate was guaranteed for the Cuban people and from other nations that may need it.
Abdala, the first vaccine candidate in Cuba and Latin America, showed a 90% effectiveness in critically-ill patients and against the Delta variant, as well as a 92,28% efficacy against symptomatic disease with.
The Abadala doses produced were destined to vaccine the Cuban people over 19, which includes pregnant women, nursing mothers, people with transplants, adolescents and young people in terminal grades of the national education system.
mh/pll/msm/nmr